BridgeMD
New treatment option for Convergence Insufficiency
Official title Non-invasive Brain Stimulation for Treating Symptomatic Convergence Insufficiency
ClinicalTrials.gov ID: NCT05877560
What this study is testing
- What it's testing
- The goal of this randomized controlled trial is to test the effectiveness of non-invasive brain stimulation in treating adults with symptomatic convergence insufficiency compared to vergence/accommodative therapy. The main questions it aims to answer are: 1.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 40. Healthy volunteers may be eligible.
You may be able to join if
- Best-corrected visual acuity of \> 20/25 in each eye at distance and near
- Exophoria at near at least 4∆ greater than at far
- Receded near point of convergence of \> 6 cm break
- Insufficient positive fusional vergence at near (\< 15∆ base-out blur or break)
- CISS score of 16 and greater for children or 21 and greater for adults
You likely can't join if
- Previously treated for convergence insufficiency with home- or office-based vergence/accommodative therapy
- Amblyopia (\> 2-line difference in best-corrected visual acuity between the two eyes)
- Constant strabismus
- History of strabismus surgery
- Convergence insufficiency secondary to acquired brain injury or neurological disorder
- Manifest or latent nystagmus
See the full eligibility criteria
- Best-corrected visual acuity of \> 20/25 in each eye at distance and near
- Exophoria at near at least 4∆ greater than at far
- Receded near point of convergence of \> 6 cm break
- Insufficient positive fusional vergence at near (\< 15∆ base-out blur or break)
- CISS score of 16 and greater for children or 21 and greater for adults
- Have had a dilated fundus examination within the last 12 months
- Informed consent and willingness to participate in the study and be assigned by chance
- Previously treated for convergence insufficiency with home- or office-based vergence/accommodative therapy
- Amblyopia (\> 2-line difference in best-corrected visual acuity between the two eyes)
- Constant strabismus
- History of strabismus surgery
- Convergence insufficiency secondary to acquired brain injury or neurological disorder
- Manifest or latent nystagmus
- Systemic disease known to affect accommodation, vergence, and ocular motility including multiple sclerosis, Graves disease, myasthenia gravis, Parkinson's disease, cerebral palsy, and diabetes
- Developmental disability, attention deficit hyperactivity disorder (ADHD), learning disability or cognitive dysfunction that would interfere with treatment
- Taking medications that can affect normal neurological function including antipsychotics, antiepileptics, and opioids
- Presence of metal or electronic implants in or on the body, including pacemakers
The study team makes the final eligibility decision.
Where it's taking place
- Downers Grove, Illinois, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 40 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Downers Grove, Illinois, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.